| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pâmela C L Ferreira, Bruna Bellaver, Guilherme Povala, Wagner S Brum, Cécile Tissot, Atef Badji, Matthew E Sloan, Andréa L Benedet, Pedro Rosa-Neto, Nicholas J Ashton, Tharick A Pascoal, Antoine Leuzy, Eduardo R Zimme. Endocannabinoid System Biomarkers in Alzheimer's Disease. Cannabis and cannabinoid research. 2022-11-17. PMID:36394442. |
endocannabinoid system biomarkers in alzheimer's disease. |
2022-11-17 |
2023-08-14 |
Not clear |
| Vasil Kecheliev, Francesco Spinelli, Adrienne Herde, Ahmed Haider, Linjing Mu, Jan Klohs, Simon M Ametamey, Ruiqing N. Evaluation of cannabinoid type 2 receptor expression and pyridine-based radiotracers in brains from a mouse model of Alzheimer's disease. Frontiers in aging neuroscience. vol 14. 2022-10-17. PMID:36248003. |
evaluation of cannabinoid type 2 receptor expression and pyridine-based radiotracers in brains from a mouse model of alzheimer's disease. |
2022-10-17 |
2023-08-14 |
mouse |
| Alberto Llorente-Ovejero, Iker Bengoetxea de Tena, Jonatan Martínez-Gardeazabal, Marta Moreno-Rodríguez, Laura Lombardero, Iván Manuel, Rafael Rodríguez-Puerta. Cannabinoid Receptors and Glial Response Following a Basal Forebrain Cholinergic Lesion. ACS pharmacology & translational science. vol 5. issue 9. 2022-09-16. PMID:36110372. |
the endocannabinoid system modulates learning, memory, and neuroinflammatory processes, playing a key role in neurodegeneration, including alzheimer's disease (ad). |
2022-09-16 |
2023-08-14 |
rat |
| Ana Carolina Ruver-Martins, Maíra Assunção Bicca, Fabiano Soares de Araujo, Beatriz Helena Lameiro de Noronha Sales Maia, Fabrício Alano Pamplona, Elton Gomes da Silva, Francisney Pinto Nasciment. Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer's disease symptoms: a case report. Journal of medical case reports. vol 16. issue 1. 2022-07-12. PMID:35820856. |
cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic alzheimer's disease symptoms: a case report. |
2022-07-12 |
2023-08-14 |
Not clear |
| Yolanda Paes-Colli, Andrey F L Aguiar, Alinny Rosendo Isaac, Bruna K Ferreira, Raquel Maria P Campos, Priscila Martins Pinheiro Trindade, Ricardo Augusto de Melo Reis, Luzia S Sampai. Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in cellular neuroscience. vol 16. 2022-06-16. PMID:35707521. |
in clinical practice, cannabis products have already been introduced to treatment regimens of alzheimer's disease, parkinson's disease and multiple sclerosis's patients, and the mechanisms of action behind the reported improvement in the clinical outcome and disease progression are associated with their anti-inflammatory, immunosuppressive, antioxidant, and neuroprotective properties, due to the modulation of the endocannabinoid system. |
2022-06-16 |
2023-08-14 |
Not clear |
| Yolanda Paes-Colli, Andrey F L Aguiar, Alinny Rosendo Isaac, Bruna K Ferreira, Raquel Maria P Campos, Priscila Martins Pinheiro Trindade, Ricardo Augusto de Melo Reis, Luzia S Sampai. Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in cellular neuroscience. vol 16. 2022-06-16. PMID:35707521. |
in this review, we describe the role played by the endocannabinoid system in the physiopathology of alzheimer, parkinson, and multiple sclerosis, mainly at the neuroimmunological level. |
2022-06-16 |
2023-08-14 |
Not clear |
| Clémence Lacroix, Isabelle Alleman-Brimault, Arnaud Zalta, Frank Rouby, Catherine Cassé-Perrot, Elisabeth Jouve, Laurence Attolini, Romain Guilhaumou, Joëlle Micallef, Olivier Bli. What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps? Frontiers in pharmacology. vol 13. 2022-05-16. PMID:35571129. |
as we know that the endocannabinoid system is largely involved in neurological disorders, we focused on the scientific rationale of medical cannabis in three neurological disorders: amyotrophic lateral sclerosis, parkinson's disease, and alzheimer's disease through pharmacological plausibility, clinical studies, and patients' view. |
2022-05-16 |
2023-08-13 |
Not clear |
| Fenqin Chen, Jun Bai, Shanshan Zhong, Rongwei Zhang, Xiaoqian Zhang, Ying Xu, Mei Zhao, Chuansheng Zhao, Zhike Zho. Molecular Signatures of Mitochondrial Complexes Involved in Alzheimer's Disease via Oxidative Phosphorylation and Retrograde Endocannabinoid Signaling Pathways. Oxidative medicine and cellular longevity. vol 2022. 2022-04-18. PMID:35432724. |
molecular signatures of mitochondrial complexes involved in alzheimer's disease via oxidative phosphorylation and retrograde endocannabinoid signaling pathways. |
2022-04-18 |
2023-08-13 |
Not clear |
| b' Emine Petekkaya, Berna Ku\\xc5\\x9f, Serdar Do\\xc4\\x9fan, Hanifi Bayaro\\xc4\\x9fullar\\xc4\\xb1, Turay Mutlu, \\xc4\\xb0smet Murat Melek, Abdullah Arpac\\xc4\\xb. Possible role of endocannabinoids in olfactory and taste dysfunctions in Alzheimer\'s and Parkinson\'s patients and volumetric changes in the brain. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 100. 2022-04-10. PMID:35398594.' |
the purpose of this study is to determine the volumes of primary brain regions associated with smell and taste in alzheimer's and parkinson's patients and healthy controls using mr imaging and examine volumetric changes in comparison to smell/taste questionnaire and test results and endocannabinoid (ec) levels. |
2022-04-10 |
2023-08-13 |
human |
| Alexandru Vasincu, Răzvan-Nicolae Rusu, Daniela-Carmen Ababei, Mădălina Larion, Walther Bild, Gabriela Dumitrița Stanciu, Carmen Solcan, Veronica Bil. Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty. Biology. vol 11. issue 3. 2022-03-26. PMID:35336814. |
the present review will explore the roles of cannabinoid receptors (cbrs) and pharmacological agents that modulate cbrs or ecs activity with reference to alzheimer's disease (ad), parkinson's disease (pd), huntington's disease (hd) and multiple sclerosis (ms). |
2022-03-26 |
2023-08-13 |
Not clear |
| Shivanshu Bajaj, Saima Zameer, Shreshta Jain, Vaishali Yadav, Divya Vohor. Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer's Disease-like Sporadic Dementia in Mice with an Emphasis on Aβ, HSP-70, Neuroinflammation, and Oxidative Stress. ACS chemical neuroscience. 2022-03-22. PMID:35316021. |
recently, pharmacological inhibition of endocannabinoid (ecb)-degrading enzymes, fatty acid amide hydrolase (faah) and monoacylglycerol lipase (magl), is being investigated to modulate the pathology of alzheimer's disease. |
2022-03-22 |
2023-08-13 |
mouse |
| Alessandro Papa, Silvia Pasquini, Chiara Contri, Sandra Gemma, Giuseppe Campiani, Stefania Butini, Katia Varani, Fabrizio Vincenz. Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition. Cells. vol 11. issue 3. 2022-02-15. PMID:35159280. |
the endocannabinoid system (ecs) is emerging as a particularly attractive therapeutic target in cns disorders and neurodegenerative diseases including parkinson's disease (pd), alzheimer's disease (ad), huntington's disease (hd), multiple sclerosis (ms), amyotrophic lateral sclerosis (als), stroke, traumatic brain injury (tbi), pain, and epilepsy. |
2022-02-15 |
2023-08-13 |
Not clear |
| Chu Che. Endocannabinoid metabolism and Alzheimer's disease. Neural regeneration research. vol 17. issue 9. 2022-02-10. PMID:35142686. |
endocannabinoid metabolism and alzheimer's disease. |
2022-02-10 |
2023-08-13 |
Not clear |
| Shuangtao Li, Yuanbing Huang, Lijun Yu, Xiaoyu Ji, Jie W. Impact of the cannabinoid system in Alzheimer's diseases. Current neuropharmacology. 2022-02-02. PMID:35105293. |
in this review, we discuss the therapeutic potential of cannabinoids for the treatment of alzheimer's disease. |
2022-02-02 |
2023-08-13 |
human |
| Shuangtao Li, Yuanbing Huang, Lijun Yu, Xiaoyu Ji, Jie W. Impact of the cannabinoid system in Alzheimer's diseases. Current neuropharmacology. 2022-02-02. PMID:35105293. |
how cannabinoids act on different endocannabinoid receptor subtypes to regulate alzheimer's disease, the roles of the endocannabinoid system in alzheimer's disease are outlined, and the underlying mechanisms are discussed. |
2022-02-02 |
2023-08-13 |
human |
| Shuangtao Li, Yuanbing Huang, Lijun Yu, Xiaoyu Ji, Jie W. Impact of the cannabinoid system in Alzheimer's diseases. Current neuropharmacology. 2022-02-02. PMID:35105293. |
finally, we summarize the most relevant opportunities of cannabinoid pharmacology related to alzheimer's disease and discuss the potential usefulness of cannabinoids in the clinical treatment of alzheimer's disease. |
2022-02-02 |
2023-08-13 |
human |
| Deepak Kumar, Ashish Sharma, Rajeev Taliyan, Maiko T Urmera, Oscar Herrera-Calderon, Thomas Heinbockel, Shafiqur Rahman, Rohit Goya. Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling. Ageing research reviews. vol 73. 2021-12-11. PMID:34844016. |
orchestration of the circadian clock and its association with alzheimer's disease: role of endocannabinoid signaling. |
2021-12-11 |
2023-08-13 |
Not clear |
| Shivanshu Bajaj, Shreshta Jain, Preeti Vyas, Sandhya Bawa, Divya Vohor. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? Brain research bulletin. vol 174. 2021-12-10. PMID:34217798. |
the role of endocannabinoid pathway in the neuropathology of alzheimer's disease: can the inhibitors of magl and faah prove to be potential therapeutic targets against the cognitive impairment associated with alzheimer's disease? |
2021-12-10 |
2023-08-13 |
Not clear |
| Shivanshu Bajaj, Shreshta Jain, Preeti Vyas, Sandhya Bawa, Divya Vohor. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? Brain research bulletin. vol 174. 2021-12-10. PMID:34217798. |
anadamide (aea) and arachidonoyl glycerol (2-ag), as potential therapeutic targets with the ability to modify alzheimer's pathology by targeting the inflammatory, neurodegenerative and cognitive aspects of the disease. |
2021-12-10 |
2023-08-13 |
Not clear |
| Hui Jing, Alex Reed, Olesya A Ulanovskaya, Jan-Sebastian Grigoleit, Dylan M Herbst, Cassandra L Henry, Haoxin Li, Sabrina Barbas, Jason Germain, Kim Masuda, Benjamin F Cravat. Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells. Proceedings of the National Academy of Sciences of the United States of America. vol 118. issue 41. 2021-12-06. PMID:34607960. |
here, we show that phospholipase cγ2 (plcγ2 or plcg2)-mutations in which are associated with autoinflammatory disorders and alzheimer's disease-serves as a principal source of diacylglycerol (dag) pools that are converted into a cascade of bioactive endocannabinoid and eicosanoid lipids by dag lipase (dagl) and monoacylglycerol lipase (mgll) enzymes in innate immune cells. |
2021-12-06 |
2023-08-13 |
mouse |